

CONSENSUS ARTICLE

Open Access



# European headache federation consensus on the definition of resistant and refractory migraine

## Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)

Simona Sacco<sup>1,2\*</sup> , Mark Braschinsky<sup>3</sup>, Anne Ducros<sup>4</sup>, Christian Lampl<sup>5</sup>, Patrick Little<sup>6</sup>, Antoinette Maassen van den Brink<sup>7</sup>, Patricia Pozo-Rosich<sup>8,9</sup>, Uwe Reuter<sup>10</sup>, Elena Ruiz de la Torre<sup>6</sup>, Margarita Sanchez Del Rio<sup>11</sup>, Alexandra J. Sinclair<sup>12,13</sup>, Zaza Katsarava<sup>14,15,16,17</sup> and Paolo Martelletti<sup>18,19</sup>

### Abstract

**Introduction:** Despite advances in the management of headache disorders, some patients with migraine do not experience adequate pain relief with acute and preventive treatments. It is the aim of the present document to provide a definition of those migraines which are difficult-to-treat, to create awareness of existence of this group of patients, to help Healthcare Authorities in understanding the implications, and to create a basis to develop a better pathophysiological understanding and to support further therapeutic advances.

**Main body:** Definitions were established with a consensus process using the Delphi method. Patients with migraine with or without aura or with chronic migraine can be defined as having *resistant migraine* and *refractory migraine* according to previous preventative failures. *Resistant migraine* is defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating headache days per month for at least 3 consecutive months without improvement; definition can be based on review of medical charts. *Refractory migraine* is defined by having failed all of the available preventatives and suffer from at least 8 debilitating headache days per month for at least 6 consecutive months. Drug failure may include lack of efficacy or lack of tolerability. Debilitating headache is defined as headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy at the recommended dose and taken early during the attack; failure of at least two different triptans is required.

(Continued on next page)

\* Correspondence: [simona.sacco@univaq.it](mailto:simona.sacco@univaq.it)

<sup>1</sup>Neuroscience section – Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy

<sup>2</sup>Regional Referral Headache Center of the Abruzzo region, ASL Avezano-Sulmona-L'Aquila, L'Aquila, Italy

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

**Conclusions:** We hope, that the updated EHF definition will be able to solve the conflicts that have limited the use of definitions which have been put forward in the past. Only with a widely accepted definition, progresses in difficult-to-treat migraine can be achieved. This new definition has also the aim to increase the understanding of the impact of the migraine as a disease with all of its social, legal and healthcare implications. It is the hope of the EHF Expert Consensus Group that the proposed criteria will stimulate further clinical, scientific and social attention to patients who suffer from migraine which is difficult-to-treat.

**Keywords:** Migraine, Chronic migraine, Resistant migraine, Refractory migraine, Intractable migraine

## Introduction

Despite advances in the management of headache disorders, some patients with migraine do not experience adequate pain relief with acute and preventive treatments. This correlates with higher burden and disability, as well as despair of patients who suffer from it. The terms “refractory” and “intractable” headache have been used to describe this particular condition and various definitions have been suggested over time [1–6] (Table 1). However, wide acceptance of the proposed definitions was not reached so far. Moreover, the International Classification of Headache Disorders (ICHD) neither includes a definition for refractory or resistant migraine nor for other primary headaches [7].

A previous consensus statement of the European Headache Federation (EHF) defined as refractory migraine those chronic migraine patients who do not show response to adequate dosages of at least 3 drugs from the following classes: beta-blockers, anticonvulsants, tricyclics, onabotulinumtoxinA and others (e.g., flunarizine, candesartan) for at least 3 months each, in absence of medication overuse [3]. The aim of the present Consensus paper is to critically revise the definition of those migraines which are difficult-to-treat, to create awareness of existence of this group of patients, to help Healthcare Authorities in understanding the implications, and to create a basis to develop a better pathophysiological understanding and to support further therapeutic advances.

## Methods

The Panel who developed this consensus statement consisted of the members of the Council of the EHF. Ten of the board members are physicians (with specialization in Neurology or Internal medicine) and one is a pharmacologist; all are experienced in headache. The Panel includes also two representatives (PL, ERDLT) of patients from the European Migraine and Headache Alliance (EMHA). Patients representatives were not involved in the consensus process to develop the definitions but had the opportunity to provide suggestions and comments.

This Consensus represents an update of a previous EHF consensus published in 2014 [3]. All the points of the

previous EHF consensus definition were reconsidered by the EHF Expert Consensus Group and revised if necessary.

As a first step, an in-person meeting was held to agree on the need of a new Consensus Statement, on the composition of the EHF Expert Consensus Group and on the mission of this updated Consensus Statement. Thereafter, the process proceeded via e-mails.

The Delphi method [8] was used to reach consensus. According to this method, the EHF Expert Consensus Group members were assigned to open or multiple-choice questions in several rounds. Participants were instructed not to discuss the responses amongst themselves. Feedback after each round was sent only to the facilitator (SS). The facilitator collected all the answers for each round and issued an anonymized report with comments and agreement rates. Participants were then encouraged to revise their earlier answers in light of the replies of other members. Questions were repeated until a clear majority (> 70% of agreement) was reached [9]. Each Panel member (with the exclusion of EHMA representatives) had the right to vote. A step by step approach was used to build the definitions, using the results of the Delphi questions. Seven rounds were needed to reach a consensus among all the different aspects of the definition (Table 2).

## Results

Two categories of difficult to treat migraine were recognized, *resistant migraine* and *refractory migraine*. Criteria to define resistant and refractory migraine are reported in Table 3.

Definitions are based on fulfilling ICHD III criteria for migraine with or without aura or for chronic migraine [7] and having at least 8 debilitating headache days per month plus the failure of previous preventive treatments.

*Resistant migraine* is defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating headache days per month for at least 3 consecutive months without improvement; definition can be based on review of medical charts.

*Refractory migraine* is defined by having failed all of the available preventatives and suffer from at least 8

Table 1 Available definitions for migraine which is difficult to treat

Intractable migraine – Gowdsby, 2005	
Criteria	Definition
Diagnosis	Migraine (any, criteria not specified)
Medication overuse	-
Refactory definition	Failure of at least four classes, where three should come from 1–4 1 Beta-blockers 2 Anticonvulsants 3 Calcium channel blockers 4 Tricyclic antidepressants 5 Other antidepressants 6 Non-steroidal anti-inflammatory drugs 7 Metabolic enhancers, such as vitamin B2 or coenzyme Q10
Adequate trial definition	Appropriate dose Appropriate length of time Consideration of medication overuse No therapeutic or unsatisfactory effect Intolerable side-effects Contraindications to use
Failed trial definition	-

  

Intractable headache – Silberstein, 2010	
Criteria	Definition
Diagnosis	Migraine
Definition of refactory	1. Acute treatment - Class I (mild): Failure of adequate response to 2 different classes of non-specific acute treatments (eg. NSAIDs, triptans, or ergot derivatives). - Class II (moderate): Above plus failure to respond to triptans or ergot derivatives.* If contraindicated, failure to respond to oral dopamine antagonists or parenteral NSAID - Class III (severe): Above plus failure to respond to oral or parenteral opioid or corticosteroids or parenteral dopamine antagonist. *The doses and appropriate formulation 2. Preventive treatment - Class I (mild): Failure of adequate treatment trial of any of the below reported drugs (may not be contraindication) - Class II (moderate): Failure of adequate treatment trials of 2 of the below reported drugs where 1 must be from a to f and 1 from g to i - Class III (very severe): Above plus failed aggressive inpatient or outpatient treatment and/or failure to respond to declassification treatment in subjects with acute headache pain medication overuse (a) Beta-blockers; (b) Tricyclic antidepressants; (c) Verapamil or flunarizine; (d) Sodium valproate (or divalproex sodium); (e) Topiramate; (f) Combination therapy that includes at least 1 drug of type a-e; the second drug can be from any type (a-e or f); The drugs must be of different types (eg. a combination of 2 anticonvulsants is not acceptable); (g) Gabapentin; (h) Other treatments with at least 1 positive placebo-controlled trial; (i) Non-pharmacological treatments (eg. biofeedback, relaxation, physical therapy, cognitive behavioral therapy) *Oral antidepressants include amitriptyline (eg. 150 mg), nortriptyline (eg. 100 mg), doxepin (eg. 150 mg) or citalopram (eg. 60 mg) †Taper definitions include amitriptyline (eg. 150 mg), nortriptyline (eg. 100 mg), doxepin (eg. 150 mg) or citalopram (eg. 60 mg) ‡1 medication only to 3 preventive medications, where 2 must be of different types from a to i below. Failure is contingent on the headache disorder; for episodic migraine 4 is often defined as 50% reduction in frequency of headache days or attacks. For chronic migraine, treatment failure is defined as <50% reduction in headache days.
Propylactic therapies	-

  

Refactory migraine – European Headache Federation, 2014	
Criteria	Definition
Diagnosis	ICHD-III beta chronic migraine
Medication overuse	Excluded
Refactory definition	Contraindications or no effect of the following preventive medication with at least 3 drugs from the following classes: 1. Beta-blockers: Propranolol up to 240 mg/d, Metoprolol up to 200 mg, Atenolol up to 100 mg, Bisoprolol up to 10 mg 2. Anticonvulsants: Valproate acid up to 1.5 g/d, Topiramate up to 200 mg/d 3. Tricyclic antidepressants: Amitriptyline up to 100 mg/d 4. Others: Flunarizine up to 10 mg/d, Candesartan 16 mg/d 5. OnabotulinumtoxinA: 155–195 U according to the PREEMPT protocol
Adequate trial definition	Propylactic migraine medications in adequate dosages used for at least 3 months each
Additional criteria	Adequate treatment of psychiatric or other comorbidities by multidisciplinary team, if available -Secondary headache must be excluded -MR provides the underlying cause -Migraine is not the cause of medication overuse -Absence of efficacy reduction on 3A days >50% -Declassification procedure (inpatient hospital setting), intravenous, oral and advice only are all accepted

  

Refactory migraine – American Headache Society, 2008	
Criteria	Definition
Diagnosis	Episode or chronic migraine with significant disability, as defined by MIDAS >10
Medication overuse	With or without
Refactory definition	1. Failed adequate trials of preventive medicines, alone or in combination, from at least 2 of 4 drug classes: a. Beta-blockers b. Anticonvulsants c. Tricyclic antidepressants d. Calcium channel blockers 2. Failed adequate trials of abortive medicines from the following classes, unless contraindicated: a. Both a triptan and BHE intranasal or injectable formulation b. Either nonsteroidal anti-inflammatory drugs or combination analgesics c. Other nonsteroidal anti-inflammatory drugs or combination analgesics Period of time during which an appropriate dose of medicine is administered, typically at least 2 months at optimal or maximum tolerated dose, unless terminated early due to adverse effects Headaches cause significant interference with function or quality of life despite modification of triggers, lifestyle factors, and adequate trials of acute and preventive medicines with established efficacy
Adequate trial definition	-
Additional criteria	-

  

Refactory migraine – Austrian Consensus Group, 2014	
Criteria	Definition
Diagnosis	Chronic migraine according to ICHD-3-beta for at least 24 months causing significant impairment of quality of life and/or socio-economic burden
Medication overuse	Outpatient or inpatient declassification and diagnostic re-evaluation after two months of follow-up is mandatory
Refactory definition	Failure of at least 3 adequate treatments with prophylactic medication; use of drugs from at least three of the classes a-d (a) beta blockers: propranolol 80-160 mg, metoprolol 100-200 mg, bisoprolol 5-10 mg (b) anticonvulsants: valproic acid 1000-1500 mg (c) tricyclic antidepressants: up to 75 mg (d) flunarizine 5-10 mg, (e) other drugs with at least one positive randomised controlled study - e.g. lisinopril 20 mg, candesartan 20 mg, onabotulinumtoxin A 155-195U according to PREEMPT
Adequate trial definition	Adequate treatment requires the intake of specific compounds (a) from certain classes of drugs, (b) in an effective dosage, (c) over a period of at least three months
Failed trial definition	(a) no or insufficient efficacy (based on patient report and recordings in a headache diary), (b) intolerable adverse effects, (c) contraindications
Additional criteria	Modification of trigger factors and lifestyle and treatment of comorbid disorders did not improve the headache Other primary headaches such as tension headaches and new daily persistent headache as well as secondary headaches apart from medication overuse headache must be excluded Patients who have been treated with medication overuse headache and/or medication overuse headache and/or medication overuse headache (MOSH) and/or medication overuse headache (MOH) must be excluded (d) CSF pressure should be measured in patients with evidence of sinus tenses in MR venography

  

Refactory migraine – Dantona and Matharu, 2019	
Criteria	Definition
Diagnosis	ICHD-III chronic migraine
Medication overuse	Excluded <sup>a</sup>
Refactory definition	Failure to respond to 5 classes of preventive treatments (including 2 from 1 to 3 <sup>b</sup> ): 1. Topiramate 2. Minimum of two quarterly injections of Onabotulinumtoxin A 3. CGRP pathway monoclonal antibody 4. Beta-blockers (Propranolol, Metoprolol, Timolol) 5. Tricyclic antidepressants (amitriptyline) 6. SNRI (Venlafaxine) 7. Sodium valproate/Divalproex sodium 8. Other pharmacological preventive treatments with established efficacy in migraine <sup>c</sup>
Adequate trial definition	At least 2 month trial at an optimum or maximum tolerated dose (excluding the time taken for the titration or the dose), unless terminated early due to side effects <sup>d</sup>
Failed trial definition	1. Failure to respond to drug (<50% reduction in frequency and/or severity of monthly migraine days) 2. Intolerable side effects 3. Contraindication to use

ICHD-III: International Classification of Headache Disorders; MIDAS: Migraine Disability Assessment  
 a-Secondary headache must be excluded  
 b-MR provides the underlying cause  
 c-Migraine is not the cause of medication overuse  
 d-Absence of efficacy reduction on 3A days >50%  
 -Declassification procedure (inpatient hospital setting), intravenous, oral and advice only are all accepted

**Table 2** Rounds of the consensus process. After each round and before the next one, anonymized results and comments were shared. \*Residual disagreement regarded 2 different issues from 2 different members of the group: 1. Threshold of headache days per month: 6 was the suggested alternative; 2 Assessment of patients: no need to be assessed by headache centers

Round	Task	Agree	Disagree	Unsure	Action
1	Decide to work on two different definitions: - Resistant migraine which is a form of migraine that has not responded to some treatments but where there is room to try other available treatments; - Refractory migraine which is a form of migraine that cannot be managed with any of the available treatments.	73%	18%	9%	Work on two categories
2	Use in the definition of cut-off values of headache days per month instead of percent reduction from baseline after treatment.	73%	27%	-	Use cut-off values
3	Decide on preferable cut-off values for resistant and refractory migraine. Experts were asked for each category, resistant and refractory, to fill-in with numbers the following definition: "disabling headache being present for at least ( ) days per month for ( ) months in patients who have failed or have contraindication to at least ( ) drug categories".	Members provided values			Calculation of median values
4	Decide to add $\pm 2$ days to the number of headache days selected as threshold (e.g. headache being present for at least $8 \pm 2$ days per month).	63%	37%	-	Rejected
	Provide a list of the drug categories to have failed to meet definitions of resistant and refractory.	Members provided a list			-
5	Provide free comments on the first draft of the definition. Issues to be commented were: - Criteria to define resistant and refractory migraine - Drug classes to have failed to meet criteria - Definition of debilitating migraine - Definition of drug failure - Definition of contraindications - Assessment of patients - Medication overuse - Behavioral factors - Comorbidities	Members provided comments			Comments received and considered to improve the proposal
6	Provide comments on the second draft of the definition	Members provided comments			Comments received and considered to improve the proposal
7	Agree on the third draft of the definition	82%	18%*	-	Final definition agreed

debilitating headache days per month for at least 6 consecutive months. For refractory migraine, chart review alone is not sufficient and a minimum period of observation of 6 months is required together with completed diaries.

The drug classes considered for meeting the definitions include antidepressants, antiepileptics, beta-blockers, calcium channel blockers, drugs acting on the calcitonin-gene related peptide (CGRP) pathway, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, onabotulinumtoxinA, as well as any new developed drug with established efficacy in migraine prevention. Drug failure may include lack of efficacy or lack of tolerability. For lack of efficacy, appropriate dosing and duration of the considered preventatives is reported in Table 4.

A patient cannot be considered to try some drugs because of possible contraindications. Absolute, major and relative contraindications to drugs for migraine prevention are reported in Table 5.

The presence of medication overuse is compatible with the proposed definition of resistant and refractory migraine; however, in patients with refractory migraine documentation of failed attempts of withdrawal of medications is needed.

Both definitions of resistant and refractory migraine require the presence of at least 8 days of debilitating migraine. Debilitating headache is defined as headache causing serious impairment to conduct activities of daily

living despite the use of pain-relief drugs with established efficacy at the recommended dose and taken early during the attack; failure of at least two different triptans is required.

To validate the definitions, it is also recommended that patients with resistant migraine are evaluated by headache specialists and that patients with refractory migraine are evaluated in tertiary Headache Centers.

Triggers and comorbidities which may contribute to resistant or refractory migraine need to be identified and managed before assigning patients to those categories. Careful differential diagnosis with mimicking conditions must be done as suggested in Table 6.

## Discussion

### Resistant and refractory

It is necessary to distinguish between patients who easily respond to treatment and those who do not. The latter requires more attention and more persistence in the treatment. Moreover, patients who do not easily respond to treatment are at higher risk of developing chronic headache and therefore should be identified early and treated accordingly [10].

One of the major novelties of the updated EHF Consensus definition is the recognition that difficult-to-treat patients may be labelled into two major categories, *resistant migraine* and *refractory migraine*; the difference

**Table 3** Proposed updated definition of resistant and refractory migraine

<p>Resistant migraine can be diagnosed if all the following criteria are met:</p> <p>A. Established diagnosis of 1.1 Migraine without aura and/or 1.2 Migraine with aura or 1.3 Chronic migraine according to ICHD-III criteria;</p> <p>B. Debilitating headache for at least 8 days per month for at least 3 months;</p> <p>C. Failure and/or contraindication to 3 drug classes<sup>a</sup> with established evidence for migraine prevention, given at an appropriate dose for an appropriate duration.</p>	<p>Refractory migraine can be diagnosed if all the following criteria are met:</p> <p>A. Established diagnosis of 1.1 Migraine without aura and/or 1.2 Migraine with aura or 1.3 Chronic migraine according to ICHD-III criteria;</p> <p>B. Debilitating headache for at least 8 days per month for at least 6 months;</p> <p>C. Failure and/or contraindication to all classes with established evidence for migraine prevention, given at an appropriate dose for an appropriate duration.</p>
<i>Specifies to the diagnosis</i>	
Definition of debilitating headache	
Debilitating headache is defined as headache causing serious impairment to conduct activities of daily living, despite the use of pain-relief drugs with established efficacy at the recommended dose, and taken at the beginning of the attack; failure of at least two different triptans is required.	
Drug classes considered for the diagnosis	
<ol style="list-style-type: none"> <li>1. Antidepressant (Amitriptyline, Venlafaxine);</li> <li>2. Antiepileptic (Topiramate or Valproate);</li> <li>3. Beta-blocker (Atenol, Metoprolol, Propranolol, Timolol);</li> <li>4. Calcium channel blocker (Flunarizine or Cinnarizine);</li> <li>5. Drugs acting on the CGRP pathway (Monoclonal antibodies and Gepants);</li> <li>6. Angiotensin-converting enzyme inhibitor (Lisinopril) or angiotensin II receptor blocker (Candesartan);</li> <li>7. OnabotulinumtoxinA (for chronic migraine only);</li> <li>8. Other pharmacologic preventive treatments with established efficacy in migraine (e.g. any new developed drug).</li> </ol>	
Definition of drug failure	
<p>Failure, at any time, of migraine preventatives because of:</p> <ol style="list-style-type: none"> <li>1. lack of efficacy due to persistence of headache with the required frequency for meeting criteria for resistant or refractory migraine, while the patient is on treatment with one of the recognized preventatives at an established dose and for an appropriate duration;<sup>b</sup></li> <li>2. lack of tolerability due to side effects which are unbearable for the patient, cannot be effectively managed and require stopping the drug.</li> </ol>	
Definition of contraindication	
Contraindication is any specific situation in which the use of a given drug is inadvisable. <sup>c</sup>	
Assessment of patients	
<p>To validate definitions, we suggest the following:</p> <ol style="list-style-type: none"> <li>1. Resistant migraine, evaluation by a Headache specialist with review of medical charts;</li> <li>2. Refractory migraine, evaluation in a tertiary level Headache Center with in-person follow-up for at least 6 months.</li> </ol>	
Medication overuse	
<ol style="list-style-type: none"> <li>1. For resistant migraine presence of medication overuse does not exclude the diagnosis;</li> <li>2. For refractory migraine presence of medication overuse does not exclude the diagnosis but attempts of unsuccessful medication withdrawal needs to be documented.</li> </ol>	
Additional factors	
<p>Triggers and comorbidities need to be considered and managed; unsuccessful management of triggers and comorbidities is possible.</p> <p>Careful differential diagnosis with mimicking conditions must be done.</p>	

<sup>a</sup>Trials with at least 3 drug classes is encouraged if allowed by contraindications

<sup>b</sup>Established doses and duration as reported in Table 4

<sup>c</sup>Absolute, major and relative contraindications as reported in Table 5

**Table 4** Suggested doses and duration for assessment of lack of efficacy

Drug	Usual dose	Minimum effective dose	Maximal effective dose	Minimum duration of treatment*
Monoclonal antibodies acting on the calcitonin-gene-related peptide pathway				
Erenumab	70-140 mg monthly	70 mg	140 mg	3 months
Fremanezumab	225 mg monthly	225 mg/monthly	225 mg/monthly	3 months
Galcanezumab	675 mg quarterly	675 mg/quarterly	675 mg/quarterly	3 months
	120 mg monthly (240 mg loading dose)	120 mg/monthly	120 mg/monthly	3 months
Antidepressants				
Amitriptyline	25 mg once a day	10 mg once a day	75 mg once a day	2 months
Venlafaxine	75-150 mg once a day	37.5 mg once a day	300 mg once a day	2 months
Antiepileptics				
Topiramate	50 mg twice a day	25 mg twice a day	100 mg twice a day	2 months
Valproate	300 mg twice a day	200 mg twice a day	1000 mg twice a day	2 months
Antihypertensives				
Candesartan	16 mg once a day	8 mg once a day	32 mg once a day	2 months
Lisinopril	20 mg once a day	5 mg once a day	40 mg once a day	2 months
Calcium channel blockers				
Cinnarizine	75 mg once a day	75 mg once a day	150 mg once a day	2 months
Flunarizine	5 mg once a day	5 mg once a day	10 mg once a day	2 months
Beta-blockers				
Atenolol	100 mg once a day	50 mg once a day	200 mg once a day	2 months
Metoprolol	100 mg once a day (extended release)	25 mg once a day	200 mg once a day (extended release)	2 months
Propranolol	40 mg twice a day	40 mg once a day	80 mg three times a day	2 months
Timolol	10 mg twice a day	5 mg twice a day	30 mg twice per day	2 months
Onabotulinumtoxin A	195 UI quarterly	155 UI quarterly	195 UI quarterly	2-3 cycles (9 months)

\*after reaching the therapeutic dose for drugs which require titration

between resistant and refractory migraine relies on the number of required previous treatment failures.

The two categories were identified in order to respond to different needs and to implement these needs in the clinical and research settings. In fact, the optimal definition of difficult to treat migraine depends on the

context and on the consequences of assigning the label. If the consequence of labeling is referral to a headache center or treatment escalation, the definition threshold should be lower than if the consequence is to develop new interventional treatments. Accordingly, resistant migraine is defined as migraine which remains significantly

**Table 5** Absolute, major and relative contraindications to drugs for migraine prevention

	Absolute	Major	Relative
Monoclonal antibodies acting on the calcitonin-gene-related peptide pathway			
Eptinezumab	-	-	Myocardial infarction or angina, stroke or transient ischemic attack, uncontrolled vascular risk factors
Erenumab	-	-	Myocardial infarction or angina, stroke or transient ischemic attack, uncontrolled vascular risk factors
Fremanezumab	-	-	Myocardial infarction or angina, stroke or transient ischemic attack, uncontrolled vascular risk factors
Galcanezumab	-	-	Myocardial infarction or angina, stroke or transient ischemic attack, uncontrolled vascular risk factors
Antidepressants			
Amitriptyline	Arrhythmias, congestive heart failure, coronary artery disease, heart block to any degree, mania, myocardial infarction, severe liver disease	Bipolar disorder, glaucoma, hepatic disease, monoamine oxidase inhibitors use, prostatic hypertrophy	Constipation, diabetes mellitus, driving or operating machinery, epilepsy, obesity, pheochromocytoma, seizure, thyroid disease
Venlafaxine	Mania	Bipolar disorder, close angle glaucoma, QT prolongation	Driving or operating machinery, epilepsy, hepatic disease, renal failure or renal impairment, uncontrolled hypertension
Antiepileptics			
Topiramate	Depression and suicidal ideation	Conditions predisposing to acidosis (ketogenic diet, severe pulmonary disease, metformin use), glaucoma, hepatic disease, nephrolithiasis, renal failure or renal impairment	Driving or operating machinery
Valproate	Liver disease, Mitochondrial disease; women of childbearing age not using precautions to avoid pregnancy	Depression and suicidal ideation	Driving or operating machinery, obesity
Antihypertensives			
Candesartan	-	Heart failure, hypotension, renal artery stenosis, renal impairment or failure	Hepatic disease, hyperkalemia
Lisinopril	-	Angioedema, renal artery stenosis, renal impairment or failure	Diabetes mellitus, hyperkalemia,
Calcium channel blockers			
Cinnarizine	-	Depression, Obesity	Driving or operating machinery, obesity, Parkinson disease or parkinsonism
Flunarizine	-	Depression, Obesity	Driving or operating machinery, obesity, Parkinson disease or parkinsonism
Beta-blockers			
Atenolol	Cardiogenic shock and hypotension, decompensated heart failure, heart block greater than first degree, Prinzmetal angina, sick sinus syndrome (without a pacemaker), symptomatic bradycardia	Asthma and chronic pulmonary obstructive disease, calcium channel blockers (diltiazem o verapamil) use, hypotension, myasthenia gravis, peripheral artery occlusive disease, pheochromocytoma, psoriasis, Raynaud phenomenon	Diabetes mellitus, depression, hyperthyroidism or thyrotoxicosis, obesity, renal impairment or failure
Metoprolol	Cardiogenic shock and hypotension, decompensated heart failure, heart block greater than first degree, Prinzmetal angina, sick sinus syndrome (without a pacemaker), symptomatic bradycardia	Asthma and chronic pulmonary obstructive disease, calcium channel blockers (diltiazem o verapamil) use, hypotension, myasthenia gravis, peripheral artery occlusive disease, pheochromocytoma, psoriasis, Raynaud phenomenon	Diabetes mellitus, depression, hyperthyroidism or thyrotoxicosis, obesity, renal impairment or failure
Propranolol	Cardiogenic shock and hypotension, decompensated heart failure, heart block greater than first degree, Prinzmetal angina, sick sinus syndrome (without a pacemaker), symptomatic bradycardia	Asthma and chronic pulmonary obstructive disease, calcium channel blockers (diltiazem o verapamil) use, hypotension, myasthenia gravis, peripheral artery occlusive disease, pheochromocytoma, psoriasis, Raynaud phenomenon	Diabetes mellitus, depression, hyperthyroidism or thyrotoxicosis, obesity, renal impairment or failure
Timolol	Cardiogenic shock and hypotension, decompensated heart failure, heart block greater than first degree, Prinzmetal angina, sick sinus syndrome (without a pacemaker), symptomatic bradycardia	Asthma and chronic pulmonary obstructive disease, calcium channel blockers (diltiazem o verapamil) use, hypotension, myasthenia gravis, peripheral artery occlusive disease, pheochromocytoma, psoriasis, Raynaud phenomenon	Diabetes mellitus, depression, hyperthyroidism or thyrotoxicosis, obesity, renal impairment or failure
OnabotulinumtoxinA	Myasthenia gravis, amyotrophic lateral sclerosis	Peripheral nerve disease	Infection at injections side

**Table 6** Conditions to be excluded before diagnosis of resistant or refractory migraine

Condition	Features
Chronic cluster headache	Excessive use of analgesics may mask the condition. It should be suspected in patients with side-locked headache and prominent autonomic features.
Hemicrania continua	It should be suspected in patients with side-locked headache and prominent autonomic features and with net response to indomethacin
New daily persistent headache	It should be suspected in cases where the headache is daily since its onset
Headache attributed to idiopathic intracranial hypertension	It should be suspected especially in young women who are obese. Criteria which increase the likelihood of the condition are represented by the presence at brain magnetic resonance of empty sella, flattening of the posterior part of the ocular globe, distension of the perioptic subarachnoid space, tortuous optic nerve, transverse sinus stenosis. Confirmed by cerebrospinal fluid pressure >25 cm cerebrospinal fluid pressure at lumbar puncture
Headache attributed to spontaneous intracranial hypotension	It should be suspected in cases where the headache is orthostatic and associated with hearing symptoms and neck stiffness, but these features may not be obvious. Clues to the diagnosis are pachymeningeal gadolinium-enhancement, and subdural fluid collections on brain magnetic resonance and identification of a leak on spinal imaging.

debilitating despite some treatment attempts. In contrast, refractory migraine is defined as migraine which remains significantly debilitating after maximal or nearly maximal number of treatment attempts. It is important to note that resistance and refractoriness may just represent more or less treatable versions of migraine attacks, rather than a separate migraine entity. The same patient might be identified as refractory at one time, but treatment responsive at another. Therefore, it may be of crucial importance to evaluate acute and prophylactic treatment response, baseline headache severity, partial response versus an all-or-none response, and the possibility of any variability in the treatment response over time [11].

The categorization of difficult-to-treat patients might be helpful in the recognition of patients in need of more expensive treatments. Additionally, the definition could help patients to gain access to reimbursement policies, work-related disability benefits, and social security benefits.

Anyhow, we duly recognize that patients who also do not meet criteria for resistant migraine (e.g. 6 debilitating migraine days per month) may need access to dedicated headache care or treatment escalation.

#### Cut-offs values

A further main novelty of the present definition is the use of cut-off values rather than percent reductions. The use of cut-off values is more in line with the ICHD III criteria while the use of percentage reductions is more in line with clinical trial criteria. Clinical trials for preventive treatment define responders as those achieving at least 50% reduction in monthly migraine/headache days with treatment as compared to baseline [12]. For chronic migraine a 30% reduction is accepted [13]. However, with the use of percent reduction, patients may be considered responders but still have a relevant number of debilitating

days with headache. To overcome this problem the EHF Expert Consensus Group opted to use 8 days per month as cut-off values. Eight days per month were chosen to consider evidence indicating that moderate disability starts after 4 migraine days per month [14–16]. Thus, the selected cut-off values allow us to consider both, episodic and chronic migraine as resistant or refractory. It is important to note that with the use of cut-off values, patients who have significant response to treatment (e.g. a patient with 30 headache days per month and with > 50% reduction in headache days with treatment) may be labelled as resistant or refractory. With advancements in migraine treatment, goals of successful treatment may become more and more ambitious and cut-off values may need to be further reduced.

#### Debilitating headache

The criteria proposed by the EHF Expert Consensus Group rely on the presence of a given number of days of debilitating headache attacks. The presence of a serious impairment in activities is a key feature of the proposed definitions. Debilitating headache was defined as headache causing serious impairment to the conduct of activities in daily living despite the use of pain-relief drugs with established efficacy at the recommended dose [17]. In order to assess the efficacy of acute headache medications, adequate timing of drug administration, dosage and formulations used, should be considered.

We opted for headache days rather than migraine days because overt migrainous features may be masked in complex patients especially in patients who overuse acute headache medication. We also voluntarily decided to use the term debilitating rather than disabling. The term disabling is more related to physical impairment caused by neurological disease such as stroke, multiple sclerosis, amyotrophic lateral sclerosis and others which cause permanent impairment in function of patients due

to physical disabilities. As the impairment related to migraine attacks is temporary if attacks are not frequent or not always severe and due to cognitive impairment and head pain but not to physical disability, a different terminology may be more appropriate. However, we are aware that patients who suffer from migraine live with anticipatory anxiety as they do not know when the next attack may occur. This fear conditions their life and that of their families, social activities and work responsibilities [18].

Ascertainment of debilitating attacks shall be done with clinical interview or with the use of validated scales in order to evaluate if headaches significantly interfere with a patient's ability to work, attend school, or participate in family or social activities. The EHF Expert Consensus Group did not choose to use cut scores at common validated instruments to measure function or disability such as the Migrant Disability Assessment (MIDAS) tool [19], the Headache Impact Test (HIT-6) scale [20], or the Headache-Attributed Lost Time (HALT) Indices [21]. We considered the fact that there is not one single Patient-Reported Outcome scale (PROs) including the magnitude of the impairment that a person with a migraine attack or frequent migraine suffers. This is, in a large part, due to the impact of migraine on cognition. When the brain can't function, there is a wide impact on many different tasks which need a wide range of instruments to capture the complexity of the disability. Indeed, the recent randomized controlled trials on migraine prevention used several tools to capture the impact of both, the disease and the treatment [22, 23]. Additionally, the choice of any cut-off score might be controversial as there are no data regarding which threshold of score change in these instruments should separate treatment failure from treatment success. Moreover, the disability instruments may not be translated or validated in certain countries. However, when available, using PROs not only helps to translate burden of disease but also tracks changes over time.

In the proposed definition, the efficacy of analgesics is also considered. In fact, resistance or refractoriness to acute or preventive treatment, are not to necessarily related. One patient may have a poor response to preventatives but a good response to analgesics. Failure of at least two triptans is required because there is evidence that switching from a triptan that is ineffective to a second one can result in positive treatment [24]. If the analgesics are able to control adequately the pain allowing patients to function normally, patients with migraine will not qualify to be categorized as resistant or refractory. It is worth mentioning that according to the proposed definitions of resistant and refractory migraine, patients who overuse symptomatic drugs and who have pain relief with them cannot be labelled as resistant or refractory.

### Drug failure

Establishing drug failure or contraindication is pivotal to identifying resistant or refractory migraine. This point should carefully be addressed in order to avoid labelling as resistant or refractory patients who are only pseudo-resistant or pseudo-refractory.

One of the main criteria to define resistance and refractoriness to treatment is the number of failed classes of medications. The specific classes were picked because they have shown clinical efficacy in randomized-controlled trials and are supported by evidence-based guidelines for migraine prevention [13, 22, 25, 26]. The Consensus group agreed to select failure of drug classes, rather than single medications, since a patient who fails a drug has a very low probability of responding to another drug within the same class based on expert opinion. However, it is important to note that different agents within a class may work by different mechanisms [2, 27] and thus we support the use of drugs in the same class, but with a different mechanism of action (e.g. topiramate and valproate). We acknowledge that some agents may be not available or accessible across all countries and that others require technical expertise (e.g. OnabotulinumtoxinA), which may limit the generalizability of the proposed definitions. National adaptations of the EHF Consensus on the definition of resistant and refractory migraine can be developed for use at the country level.

The proposed definitions of resistant and refractory migraine consider the appropriateness of doing trials with preventive treatments. Identification of factors that contribute to pseudo-resistance is important in preventing costly and potentially risky diagnostic evaluations and in avoiding inappropriate intensification of treatment. If therapy was inadequate (low dose or incorrect duration) the failure is to be reassessed. Suggested doses and durations for optimal treatment are specified in Table 4. Minimal duration of drug trials was set at 2 months (after reaching the therapeutic dose) for oral drugs in line with previous definition of refractory migraine. For monoclonal antibodies (mAbs) acting on the CGRP pathway a minimum of 3 months is required and for OnabotulinumtoxinA a minimum of 6 months, in line with available guidelines and evidence from real-life studies [13, 22, 25, 28]. Longer trials would be preferable for some drugs, but extending minimal time frame is not feasible in every case, especially in those patients who do not have any kind of improvement with the selected preventatives. On the other hand, we may consider to extend the preventive treatment if there was some improvement during the first period of treatment. Undoubtedly, decisions will have to be individualized. The EHF Expert Consensus Group decided not to pose a time frame for previous trials of preventatives (e.g. failure within the 10 previous years) as any choice would be arbitrary.



It is important to note that lack of adherence may contribute to lack of success of medical treatment. Lack of adherence is mostly due to side effects. Frequently, side effects are too bothersome for patients and lead to drug discontinuation. EHF criteria for resistant and refractory migraine include lack of tolerability among the accepted reasons of drug failure. Anyway, we want to point out that side effects should always be addressed and if possible adequately managed to promote drug adherence. A trusting physician–patient relationship, setting reasonable goals and expectations, and educating patients are key for a successful patient management. Nocebo effect may lead patients to discontinue medications because of the fear of a potential side effect [29, 30].

Some patients have medical contraindications to specific preventive treatments (Table 5). Contraindicated drugs are considered in the criteria for resistant and refractory migraine. It is important to differentiate absolute contraindications that pose a risk for the patient if the drug is used, from a relative contraindication, which does not prohibit the use of the drug but may require stricter monitoring. One limit of the current definition is that a patient can be defined as resistant while not having tried any preventive medication because of hypothetical contraindications to at least three classes.

In the current EHF definitions of resistant and refractory migraine, we did not include in the criteria the possibility to combine different preventatives to achieve a response to treatment in the criteria. Combinations of suggested preventive treatments are recommended especially when one preventive treatment decreased the attack frequency but did not control the situation satisfactorily, upon the physician's decision [31]. Combination therapy has the potential advantage to target different aspects of the pain dysfunction, with potentially better results due to the synergistic effects of different treatments. However, there is insufficient evidence to state definitively if combination therapy is clearly superior to single therapy [32–34].

#### Medication overuse

It is well known that a variable proportion of patients overusing acute headache medications may actually benefit from withdrawal [35]. However, the ideal treatment strategy for medication overuse is a matter of ongoing debate. Withdrawal cannot be achieved in every patient and relapse or continued overuse has been reported in many patients [36]. For those reasons we opted to make the presence of medication overuse compatible with the proposed definition of resistant and refractory migraine. Up to know it is unclear if withdrawal of acute medication may revert an apparent refractory headache into a tractable one. Having a well-defined definition of

refractory and resistant headache will represent the basis for research studies to establish this.

#### Triggers and comorbidities

In some cases, difficult-to-treat migraine is associated with uncontrolled trigger factors (e.g. excessive use of caffeine) and comorbidities. The role that those factors have in drug resistance is not entirely clear. On one hand, they may contribute to resistance or refractoriness to prescribed pharmacological treatment but on the other hand if medications are effective, triggers may not be able to induce migraine attacks. Triggers and comorbidities should be addressed and managed before labeling patients as resistant or refractory, even if definite removal is not always possible.

Trigger factors that can exaggerate migraine include alcohol consumption, caffeine overuse, diet, smoking and vasodilating antihypertensives. Further triggers are represented by emotional stress [37], alterations in the sleep cycle [38–40], and hormonal factors [41–43]. Management of those factors is a staple of good clinical practice. Additionally, patients suffering from migraine frequently have comorbid disorders [44–48]. The identification and management of all clinically significant comorbidities is essential before declaring a treatment failure in migraine patients. Psychiatric comorbidities and obesity may be particularly relevant in the setting of resistance or refractoriness to treatments [49, 50].

#### Differential diagnosis

A possible reason for treatment failure in patients with headache is that the diagnosis is incomplete or incorrect. When addressing patients with migraine who do not respond to treatment it is always important to reconsider the diagnosis and to rule out other primary or secondary headaches, which may entirely account for the clinical picture or which may coexist with migraine and contribute to the lack of response to treatments. Investigations should be done where appropriate to exclude secondary headaches [51]. A list of conditions mimicking resistant or refractory migraine is reported in Table 6.

Particular attention should be paid to idiopathic intracranial hypertension without papilledema (IIWP). This condition can be entirely responsible of difficult-to-treat headache or can contribute to drug resistance or refractoriness in patients who have concomitant migraine. Criteria which increase the likelihood of IIWP are represented by the presence, at brain magnetic resonance, of empty sella, flattening of the posterior part of the ocular globe, distension of the perioptic subarachnoid space, tortuous optic nerve, transverse sinus stenosis [52]. If this IIWP is suspected, a lumbar puncture with measurement of cerebrospinal fluid pressure should

be performed and patients treated according to available guidelines [52].

#### **Other limitations to the definition**

Migraine is a cyclic disorder which tends to fluctuate in frequency, severity and disability during life. Specifically, this has been investigated over the course of a year and for example, patients with chronic migraine can fluctuate into an episodic migraine phase [53]. This is why these new proposed criteria for the definition of resistant and refractory migraine have considered following also the International Classification for Headache Disorders, three consecutive months as a time frame to define at that time point in life, the presence of a resistant or refractory migraine. However, a diagnosis is not static in headache, and can change over time. If this should happen, it can always be revised.

It is also important to note that the present definition did not consider failure to devices or non-pharmacological therapies. A number of studies have shown that vagal nerve stimulation, biofeedback, relaxation, and cognitive behavior therapy are as efficacious for migraine as placebo, but still better than no improvement [54, 55]. However, behavioral treatments are less accessible, more professional-dependent and less standardized than pharmacological treatments, and in certain countries, not reimbursed by the Healthcare systems, than pharmacological treatments.

Moreover, physician-patient relationship, lifestyle changes, and other qualitative variables can also influence the response to treatment.

#### **Assessment of patients**

Migraine in general can be managed in the setting of primary care [56] or general neurology [57]. However, such settings cannot provide the necessary expertise to treat resistant and refractory patients. Patients with resistant migraine should be managed in special interest headache care settings (e.g. general practitioners with special interest in headache or neurologists, or first/second level headache clinics) and patients with refractory migraine must be managed in tertiary level headache clinics [58, 59]. In particular, refractory migraine patients must be offered the possibility of access to a multidisciplinary team.

Management by non-headache specialists often leads to perform-and-repeat exams which are not needed, thus raising the cost of migraine care [60, 61]. Additionally, incidental findings to unnecessary exams may lead to over-treatment of some conditions (e.g. patent foramen closure) or additional unnecessary examinations (e.g. thrombophilia screening in unselected patients with white matter abnormalities).

Establishing previous treatment failures ideally should be done by chart review. It is not reasonable to test

again preventive medications used in the past with no efficacy or with intolerable side effects provided that information on duration, dose and adverse events is sufficient and reliable. Unfortunately, not all patients provide charts and headache diaries. In those cases, careful collection of information from patient and relatives should be looked for with the help of the general practitioner, if available.

For patients with refractory migraine who were never followed by a headache specialist, a minimum follow-up of 6 months is suggested, to obtain reliable diaries and allows the possibility to.

further improve headache management, as the diagnosis of refractory migraine is a very serious matter, which should be carefully established.

#### **Implications to be defined as resistant or refractory migraine patient**

The diagnosis of resistant or refractory migraine may contribute to stigmatizing the patient and therefore may have profound psychological implications [62]. This is especially true because the concept seems static and unresolvable. Education and effort will have to be put in with both treating physicians and patients to help them to understand the possible fluctuations of the disease.

There could also be legal and healthcare implications. It may be possible that in certain countries only those patients with a resistant or refractory migraine may have access to newer treatments such as monoclonal Antibodies (mAbs) acting on the Calcitonin-Gen-Related-Peptide (CGRP) pathway; or in other countries, it might allow for temporary or permanent social welfare [14, 63]. Even if revisable, it does support a difficult-to-treat disorder and should facilitate access to more resources for its management.

#### **Future perspectives**

The introduction of the concept of resistant and refractory migraine will have clinical and political implications. We attempt to provide operational criteria of what intuitively has been used already. Introduction of expensive migraine preventatives such as OnabotulinumtoxinA and mAbs acting on the CGRP pathway and the expectation of further preventatives raised the question of cost effectiveness of these treatments. In many European Countries use of these treatments is restricted to the difficult-to-treat subpopulations of migraine patients. These subpopulations were defined based on frequency (e.g. in Spain more than 8 headache days per month) or non-response (e.g. in Germany more than 5 preventatives for episodic migraine and 6 preventatives including OnabotulinumtoxinA for chronic migraine). This manuscript aims to provide solid expert-opinion based criteria for these subpopulations. It will be important to have adequate field-testing of the proposed updated EHF

definition of resistant and refractory migraine in order to identify possible deficiencies and to make further improvements. Field-testing should be performed across different countries and different clinical settings. Adaptations at the country level may be needed to make the definition more usable.

Accepted and reliable criteria represents the basis of further research. At present, the exact pathophysiology of refractory migraine is unknown. It is important to reliably identify factors which may lead to refractoriness. We do not know whether genetic predisposition plays a role in resistance to treatment, whether resistance is accompanied over time by changes in the brain structure and function as assessed by neuroimaging, or which mechanisms play a pivotal role (e.g. central sensitization, peripheral sensitization).

There are several migraine preventive treatments in development; the proposed criteria will allow inclusion of these treatments when there is a good evidence basis for their use. Criteria will need to be changed when new treatments and significant advancements in the migraine field will happen.

## Conclusion

Crafting an operational definition of so called “difficult-to-treat migraine” is challenging. However, we all need to be aware that these patients exist and that a good definition represents a major need for clinical practice, for legal issues, and for research purposes. The proposed updated EHF definition identifies two subsets of difficult-to-treat migraine, resistant and refractory migraine, and considers both frequency and disability from single and frequent attacks. Although, in the previous literature formal and operational definitions for refractory or intractable headache were proposed, none was universally accepted. We hope, that the updated EHF definition will be able to solve the conflicts that have limited the use of definitions which have been put forward in the past. Only with a widely accepted definition, progresses in difficult-to-treat migraine can be achieved, underlying mechanisms can be identified, epidemiology can be characterized, and evidence-based treatments can be developed. Furthermore, the aim of this new definition is to increase the understanding of the impact of migraine as a disease with all of its social, legal and healthcare implications. It is the hope of the EHF Expert Consensus Group that the proposed criteria will stimulate further clinical, scientific and social attention to patients who suffer from migraine which is difficult-to-treat.

## Abbreviations

CGRP: Calcitonin-gene related peptide; EHF: European Headache Federation; EHMA: European Migraine & Headache Alliance; HALT: Headache-Attributed Lost Time; HIT-6: Headache Impact Test; ICHD: International Classification of Headache Disorders; IHW: Idiopathic intracranial hypertension without papilledema; mAbs: Monoclonal antibodies; MIDAS: Migraine Disability Assessment; PROs: Patient-Reported Outcome scale

## Acknowledgements

Not applicable.

## Authors' contributions

SS conceived this consensus, acted as facilitator during the consensus process and drafted the paper; MB, AD, ZK, CL, PM, AMVDB, PPR, UR, MSDR, AJ S contributed to develop the consensus definition and revised the paper for important intellectual content; PL and ERDLT revised the paper for important intellectual content. All authors have approved the submitted version.

## Authors' information

European Headache Federation (EHF) Council: ZK (president), CL (1st vice-president), AMVDB (2nd vice-president), SS (treasurer), PM (past-president), MB (member), PPR (member), UR (member), MSDR (member), AS (member), AD (member).

European Migraine & Headache Alliance (EMHA): PL (president), ERDLT (Executive Director, Company Secretary and Immediate Past President).

## Funding

Publication fees for this publication were covered by the European Headache Federation.

## Availability of data and materials

Not applicable.

## Ethics approval and consent to participate

Not applicable.

## Consent for publication

Not applicable.

## Competing interests

Mark Braschinsky: Fees as a speaker or for participation to advisory boards from Abbott Laboratories, Allergan Inc., Berlin-Chemie AG (Menarini Group), Boehringer Ingelheim Pharma GmbH, Desitin Arzneimittel GmbH, EV3, Gedeon Richter Ltd., GlaxoSmithKline, KBM Pharma Ltd., H. Lundbeck A/S, Novartis Pharma Services Inc., Nycomed SEFA, Orion Pharma, Pfizer Inc., Sanofi-Aventis, Sandoz d.d., Scanmed Group, Solvay Pharmaceuticals, Teva Pharmaceutical Industries Ltd./Sicor Biotech UAB, Zentiva International. Previously consultant for H. AbbePharma GmbH, Merz Pharmaceuticals. Anne Ducros: Fees as speaker or participation to advisory boards from Eli-Lilly, Novartis, Teva. Zaza Katsarava: Fees as speaker or participation to advisory boards from Novartis, Lilly, TEVA, Allergan, Merck and Daiichi. Christian Lamp: Fees as speaker or for participation to advisory boards from Allergan, Eli-Lilly, Novartis, Pfizer, Teva. Patrick Little: none. Paolo Martelletti: Fees as speaker or for participation to advisory boards from Allergan, Eli-Lilly, Novartis, Teva. Antoinette Massen van den Brink: Research grant and/or speaker/consultant fees from Amgen/Novartis, Eli-Lilly, Teva. Patricia Pozo-Rosich: Fees as consultant and speaker for Allergan, Almirall, Biohaven, Chiesi, The Corpus, Eli Lilly, Medscape, Neurodiem, Novartis and Teva. Research funding from Allergan, AGAUR, la Caixa foundation, Migraine Research Foundation, Instituto Investigación Carlos III, MICINN, Novartis, PERIS, ERANet Neuron; funding for clinical trials from Alder, Electrocore, Eli Lilly, Novartis and Teva. Uwe Reuter: Fees as consultant and speaker for Allergan, Biohaven, The Corpus, Eli Lilly, Medscape, Novartis, STREAMedUP and Teva. Research funding from BMBF and Novartis, Institutional funding for clinical trials from Alder, Amgen, Allergan, Eli Lilly, Novartis and Teva. Elena Ruiz de la Torre: none. Simona Sacco: Fees as speaker or for participation to advisory boards from Abbott, Allergan, Eli-Lilly, Medscape, Novartis, Teva. Margarita Sanchez Del Rio: Fees as speaker or for participation to advisory boards from Allergan, Eli-Lilly, Novartis, Teva. Alexandra J Sinclair: Fees as speaker from Novartis and Allergan.

## Author details

<sup>1</sup>Neuroscience section – Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.

<sup>2</sup>Regional Referral Headache Center of the Abruzzo region, ASL Avezano-Sulmona-L'Aquila, L'Aquila, Italy. <sup>3</sup>Headache Clinic, Department of Neurology, Tartu University Clinics, Tartu, Estonia. <sup>4</sup>Headache Unit, Neurology Department, Montpellier University Hospital and Montpellier University, Montpellier, France. <sup>5</sup>Department of Neurology, Headache Medical Centre Linz, Hospital Barmherzige Brüder, Centre of Integrative Medicine (ZIAM) Ordensklinikum Linz, Linz, Austria. <sup>6</sup>European Migraine & Headache Alliance (EMHA), Hendrik Ido Ambacht, The Netherlands. <sup>7</sup>Division of Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. <sup>8</sup>Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain. <sup>9</sup>Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Department de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. <sup>10</sup>Charité Universitätsmedizin Berlin, Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany. <sup>11</sup>Neurology department, Clinica Universidad de Navarra, Madrid, Spain. <sup>12</sup>Metabolic Neurology, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. <sup>13</sup>Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK. <sup>14</sup>Evangelical Hospital Unna, Unna, Germany. <sup>15</sup>Department of Neurology, University of Duisburg-Essen, Essen, Germany. <sup>16</sup>EVEX Medical Corporation, Tbilisi, Georgia. <sup>17</sup>IM Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation. <sup>18</sup>Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy. <sup>19</sup>Regional Referral Headache Center of the Lazio region, Sant'Andrea Hospital, Rome, Italy.

Received: 28 February 2020 Accepted: 25 May 2020

Published online: 16 June 2020

## References

- D'Antona L, Matharu M (2019) Identifying and managing refractory migraine: barriers and opportunities? *J Headache Pain* 23:20
- Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D (2006) Towards a definition of intractable headache for use in clinical practice and trials. *Cephalalgia* 26:1168–1170
- Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A, Russell MB, Mitsikostas DD, Jensen RH (2014) Refractory chronic migraine: a consensus statement on clinical definition from the European headache federation. *J Headache Pain* 15:47
- Schulman EA, Lake AE 3rd, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, Lipton RB (2008) Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American headache society. *Headache* 48:778–782
- Silberstein SD, Dodick DW, Pearlman S (2010) Defining the pharmacologically intractable headache for clinical trials and clinical practice. *Headache* 50:1499–1406
- Wöber C, Wessely P, Austrian Consensus Group on Refractory Chronic Migraine (2014) Comment on: Martelletti et al. Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. *J Headache Pain* 15:77
- Headache Classification Subcommittee of The International Headache Society (2018) The international classification of headache disorders 3<sup>rd</sup> edition. *Cephalalgia* 38:1–211
- Dalkey NC, Helmer-Hirschberg O (1962) An experimental application of the Delphi method to the use of experts. Rand Corp, Santa Monica
- von der Gracht HA (2013) Consensus measurement in Delphi studies: review and implications for future quality assurance. *Technol Forecast Social Change* 79:1525–1536
- Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A, Diener HC, Limmroth V (2004) Incidence and predictors for chronicity of headache in patients with episodic migraine. *Neurology* 62:788–790
- Lampl C, Jensen R, Martelletti P, Mitsikostas DD (2014) Refractory headache: one term does not cover all—a statement of the European headache federation. *J Headache Pain* 15:50
- Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee (2018) Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. *Cephalalgia* 38:815–832
- Bendtsen L, Sacco S, Ashina M, Mitsikostas DD, Ahmed F, Pozo-Rosich P, Martelletti P (2018) Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European headache federation. *J Headache and Pain* 19:91
- Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC, Ruiz de la Torre E, Craven A, Rasmussen AV, Evans S, Laflamme AK, Fink R, Walsh D, Dumas P, Vo P (2018) My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. *J Headache Pain* 19:115
- Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM (2018) Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine. *Headache* 58:1579–1592
- Torres-Ferrus M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo-Rosich P (2017) When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. *Cephalalgia* 37:104–113
- Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. *Headache* 55:3–20
- Lampl C, Thomas H, Tassorelli C, Katsarava Z, Láinez JM, Lanteri-Minet M, Rastenyte D, Ruiz de la Torre E, Stovner LJ, Andrée C, Steiner TJ (2016) Headache, depression and anxiety: associations in the Eurolight project. *J Headache Pain* 17:59
- Lipton RB, Stewart WF, Sawyer J, Edmeads JG (2001) Clinical utility of an instrument assessing migraine disability: the migraine disability assessment (MIDAS) questionnaire. *Headache* 41:854–861
- Pryse-Phillips W (2002) Evaluating migraine disability: the headache impact test instrument in context. *Can J Neurol Sci* 29(Suppl 2):S11–S15
- Steiner TJ, Lipton RB (2018) Lifting the burden: the global campaign against headache (2018) the headache-attributed lost time (HALT) indices: measures of burden for clinical management and population-based research. *J Headache Pain* 19:12
- Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. *J Headache Pain* 20:6
- Torres-Ferrus M, Alpuente A, Pozo-Rosich P (2019) How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective. *Curr Opin Neurol* 32:395–404
- Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ (2013) Triptan nonresponders: do they exist and who are they? *Cephalalgia* 33:891–896
- American Headache Society (2019) The American headache society position statement on integrating new migraine treatments into clinical practice. *Headache* 59:1–18
- Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS, European Federation of Neurological Societies (2009) EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. *Eur J Neurol* 16: 968–981
- D'Amico D, Leone M, Grazzi L, Bussone G (2008) When should “chronic migraine” patients be considered “refractory” to pharmacological to pharmacological prophylaxis? *Neurol Sci* 29:S55–S58
- Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli M, Viola S, Cerone D, Marini C, Pistoia F, Sacco S (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, Central Italy. *J Headache Pain* 21:32
- Mitsikostas DD, Mantonakis LI, Chalarakis NG (2011) Nocebo is the enemy, not placebo: a meta-analysis of reported side effects after placebo treatment in headaches. *Cephalalgia* 31:550–561
- Mitsikostas DD (2012) Nocebo in headaches: implications for clinical practice and trial design. *Curr Neurol Neurosci Rep* 12:132–137
- Krymchantowski AV, Bigal ME (2006) Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. *Expert Rev Neurother* 6:283–289
- Krymchantowski AV, da Cunha JC, Bigal ME (2012) Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. *J Headache Pain* 13:53–59
- Pascual J, Leira R, Láinez J (2003) Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. *Cephalalgia* 23:961–962
- Pascual J, Rivas M, Leira R (2007) Testing the combination beta-blocker plus topiramate in refractory migraine. *Acta Neurol Scand* 115:81–83
- Scher AI, Rizzoli PB, Loder EW (2017) Medication overuse headache: an entrenched idea in need of scrutiny. *Neurology* 89:1296–1304

36. Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC (2001) Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. *Eur Neurol* 45:229–235
37. Holm JE, Lokken C, Myers TC (1997) Migraine and stress: a daily examination of temporal relationships in women migraineurs. *Headache* 37:553–558
38. Fernández-de-Las-Peñas C, Fernández-Muñoz JJ, Palacios-Ceña M, Parás-Bravo P, Cigarán-Méndez M, Navarro-Pardo E (2017) Sleep disturbances in tension-type headache and migraine. *Ther Adv Neurol Disord* 11: 1756285617745444
39. Freedom T, Evans RW (2013) Headache and sleep. *Headache* 53:1358–1366
40. Lateef T, Witonsky K, He J, Ries Merikangas K (2019) Headaches and sleep problems in US adolescents: findings from the National Comorbidity Survey - adolescent supplement (NCS-A). *Cephalalgia* 39:1226–1235
41. Ripa P, Ornello R, Degan D, Tiseo C, Stewart J, Pistoia F, Carolei A, Sacco S (2015) Migraine in menopausal women: a systematic review. *Int J Women's Health* 7:773–782
42. Sacco S, Merki-Feld GS, Ægidius KL, Bitzer J, Canonico M, Kurth T, Lamp C, Lidsgaard O, MacGregor A, Maassen VanDenBrink A, Mitsikostas D, Nappi RE, Ntaios G, Sandset PM, Martelletti P, on behalf of the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC) (2017) Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European headache federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). *J Headache Pain* 18:108
43. Sacco S, Ægidius KL, Bitzer J, Canonico M, Gantenbein AR, Kurth T, Lamp C, Lidsgaard Ø, MacGregor AE, MaassenVanDenBrink A, Merki-Feld GS, Mitsikostas DD, Nappi RE, Ntaios G, Paemeleire K, Sandset PM, Terwindt G, Vetvik KG, Martelletti P (2018) Use of estrogens and progestogens in women of reproductive age and their effect on migraine: a consensus statement from the European headache federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). *J Headache and Pain* 19:76
44. Sacco S, Olivieri L, Bastianello S, Carolei A (2006) Comorbid neuropathologies in migraine. *J Headache Pain* 7:222–230
45. Sacco S, Cerone D, Carolei A (2008) Comorbid neuropathologies in migraine: an update on cerebrovascular and cardiovascular aspects. *J Headache Pain* 9:237–248
46. Sacco S, Ricci S, Carolei A (2012) Migraine and vascular diseases: potential implications for management. *Cephalalgia* 32:785–795
47. Sacco S, Kurth T (2014) Migraine and the risk of stroke and cardiovascular disease. *Curr Cardiol Rep* 16:524
48. Sacco S, Pistoia F, Degan D, Carolei A (2015) Conventional vascular risk factors: their role in the association between migraine and cardiovascular diseases. *Cephalalgia* 35:146–164
49. Gelaye B, Sacco S, Brown WJ, Nitchie H, Ornello R, Peterlin BL (2017) Body composition status and the risk of migraine: a meta-analysis. *Neurology* 88: 1795–1804
50. Ornello R, Ripa P, Pistoia F, Degan D, Tiseo C, Carolei A, Sacco S (2015) Migraine and body mass index categories: a systematic review and meta-analysis of observational studies. *J Headache Pain* 16:27
51. Mitsikostas DD, Ashina M, Craven A, Diener HC, Goadsby PJ, Ferrari MD, Lampl C, Paemeleire K, Pascual J, Siva A, Olesen J, Osipova V, Martelletti P, EHF committee (2015) European headache federation consensus on technical investigation for primary headache disorders. *J Headache Pain* 17:5
52. Hoffmann J, Mollan SP, Paemeleire K, Lampl C, Jensen RH, Sinclair AJ (2018) European headache federation guideline on idiopathic intracranial hypertension. *J Headache Pain* 19:93
53. Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, Buse DC (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. *J Headache Pain* 18:101
54. Diener HC, Goadsby PJ, Ashina M, Al-Karaghli MA, Sinclair A, Mitsikostas D, Magis D, Pozo-Rosich P, Irimia Seira P, Láinez MJ, Gaul C, Silver N, Hoffmann J, Marin J, Liebler E, Ferrari MD (2019) Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial. *Cephalalgia* 39: 1475–1487
55. Pistoia F, Sacco S, Carolei A (2013) Behavioral therapy for chronic migraine. *Curr Pain Headache Rep* 17:304
56. Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P (2019) Aids to management of headache disorders in primary care (2nd edition) : on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. *J Headache Pain* 20:57
57. Becker WJ, Christie SN, Mackie G, Cooper P; Canadian Headache Society Migraine Strategy Task Force (2010) Consensus statement: the development of a national Canadian migraine strategy. *Can J Neurol Sci* 37:449–456
58. Steiner TJ, Antonaci F, Jensen R, Láinez MJ, Lanteri-Minet M, Valade D (2011) Recommendations for headache service organisation and delivery in Europe. *J Headache Pain* 12:419–426
59. Marmura MJ, Hou A (2019) Inpatient Management of Migraine. *Neurol Clin* 37:771–788
60. Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P (2012) Cost of healthcare for patients with migraine in five European countries: results from the international burden of migraine study (IBMS). *J Headache Pain* 13:361–378
61. Negro A, Sciatella P, Rossi D, Guglielmetti M, Martelletti P, Mennini FS (2019) Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. *J Headache Pain* 20:120
62. Young WB, Park JE, Tian IX, Kempner J (2013) The stigma of migraine. *PLoS One* 8:e54074
63. Sabariego C, Coenen M, Ito E, Fheodoroff K, Scaratti C, Leonardi M, Vlachou A, Stavroussi P, Breclj V, Kovačič DS, Esteban E (2018) Effectiveness of integration and re-integration into work strategies for persons with chronic conditions: a systematic review of European strategies. *Int J Environ Res Public Health* 15:552

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)



## Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

[onlineservice@springernature.com](mailto:onlineservice@springernature.com)